BioSpace News Archive

Research Collaboration on Two Targeted Oncology Programs in the Ras/Raf/MAP Kinase Pathway Redx to Receive $10 Million Upfront and $10 Million in Year 2 with up to $400 Million in Further Milestone Payments Plus Tiered Royalties on any Future Net Product Sales

- Patients with locally advanced or metastatic solid tumors are being enrolled and dosed with SRK-181 in combination with anti-PD-(L)1 therapy in Part A2 of the DRAGON Phase 1 clinical trial - An update on Part A dose escalation is expected in the fourth quarter of 2020; Part B efficacy and safety data from the trial anticipated starting in 2021

Bio-Path Holdings, Inc. announced that Peter H. Nielsen, Chief Executive Officer, will present a corporate overview at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:30 a.m. ET.

Beyond Air, Inc. (NASDAQ: XAIR), today announced that two e-poster presentations have been accepted for the CHEST 2020 Annual Meeting, which is being held from October 18th to 21st.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing.

MyoKardia, Inc. (Nasdaq: MYOK) today announced that the first patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.

Smith+Nephew, the global medical technology business, announces the launch of the HEALICOIL KNOTLESS Suture Anchor, expanding its revolutionary line of Advanced Healing Solutions for rotator cuff repair.

MYOS RENS Technology, Inc. (“MYOS”) (NASDAQ: MYOS), “The Muscle Health Company” and owner of the advanced nutrition supplement Fortetropin®, announced today that it has hired The S3 Agency (S3)

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that Timothy C. Rodell , M.D., Chief Executive Officer, is scheduled to provide an overview of the Company on Monday, Sept. 14 , at 2:00 p.m. EDT

Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, announced today that it will be featured as a presenting company at the 22nd Annual Global Investment Conference sponsored by H.C Wainwright.